Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants

Molecular Diagnosis and Therapy

Volumn 14, Issue 1, 2010, Pages 23-30

  Wijnen, Petal A ^a,b   Linssen, Catharina F ^a   Haenen, Guido R ^b   Bekers, Otto ^a,b   Drent, Marjolein ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; COUMARIN; CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 76949091498     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256350     Document Type: Article

References (26)

1. Sharma P, Bentley P. Of rats and men: superwarfarin toxicity. Lancet 2005 Feb 12-18; 365 (9459): 552-553
2. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003 Aug 14; 349 (7): 631-639 (Pubitemid 36975995)
3. Erdogan D, Kocaman O, Oflaz H, et al. Alveolar hemorrhage associated with warfarin therapy: a case report and literature review. Int J Cardiovasc Imaging 2004 Apr; 20 (2): 155-159
4. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 Jun 2; 352 (22): 2285-2293
5. De Lassence A, Fleury-Feith J, Escudier E, et al. Alveolar hemorrhage: diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 1995 Jan; 151 (1): 157-163
6. Laposata M, Van Cott EM, Lev MH. Case records of the Massachusetts General Hospital: case 1-2007. A 40-year-old woman with epistaxis, hematemesis, and altered mental status. N Engl J Med 2007 Jan 11; 356 (2): 174-182
7. Krynetskiy E, McDonnell P. Building individualized medicine: prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther 2007 Aug; 322 (2): 427-434
8. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002 Apr 3; 287 (13): 1690-1698
9. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000 Nov; 28 (11): 1284-1290
10. Linssen KC, Jacobs JA, Poletti VE, et al. Reactive type II pneumocytes in bronchoalveolar lavage fluid. Acta Cytol 2004 Jul-Aug; 48 (4): 497-504
11. Geisen C, WatzkaM, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005 Oct; 94 (4): 773-779
12. Tamminga WJ,Wemer J, Oosterhuis B, et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001 Dec; 57 (10): 717-722
13. Barnett VT, Bergmann F, Humphrey H, et al. Diffuse alveolar hemorrhage secondary to superwarfarin ingestion. Chest 1992 Oct; 102 (4): 1301-1302
14. Drent M, Wessels S, Jacobs JA, et al. Association of diffuse alveolar haemorrhage with acquired vitamin K deficiency. Respiration 2000; 67 (6): 697
15. Rahman I, Skwarska E, Henry M, et al. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med 1999 Jul; 27 (1-2): 60-68
16. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation.NEngl J Med 2008Mar 6; 358 (10): 999-1008
17. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 Jun; 133 (6 Suppl.): 160-98S
18. Sconce E, Avery P, Wynne H, et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007 Mar 15; 109 (6): 2419-2423
19. Oldenburg J, Bevans CG, Fregin A, et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007 Sep; 98 (3): 570-578
20. Wijnen PA, Drent M, Nelemans PJ, et al. Role of cytochrome p450 polymorphisms in the development of pulmonary drug toxicity: a casecontrol study in the Netherlands. Drug Saf 2008; 31 (12): 1125-1134
21. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005 Apr; 93 (4): 700-705
22. Sconce EA, Khan TI,Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005 Oct 1; 106 (7): 2329-2333
23. Cooper GM, Johnson JA, Langaee TY, et al. Agenome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008 Aug 15; 112 (4): 1022-1027
24. Wang D, Chen H, Momary KM, et al. Regulatory polymorphism in vitaminK epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008 Aug 15; 112 (4): 1013-1021
25. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005 Jul 1; 106 (1): 135-140
26. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008 Feb; 25 (1): 45-51